<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320227</url>
  </required_header>
  <id_info>
    <org_study_id>ST-7557</org_study_id>
    <nct_id>NCT02320227</nct_id>
  </id_info>
  <brief_title>A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Church &amp; Dwight Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Church &amp; Dwight Company, Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety of a personal lubricant when used as indicated as a personal lubricant
      in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a
      population of healthy females
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Observed Local Erythema</measure>
    <time_frame>14 Days</time_frame>
    <description>Number of participants with observed local erythema by OB/GYN examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Observed Local Edema</measure>
    <time_frame>14 days</time_frame>
    <description>Number of participants with observed edema by OB/GYN examination.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Erythema</condition>
  <condition>Edema</condition>
  <arm_group>
    <arm_group_label>Miami w/o frag Personal lubricant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Miami w/o frag Personal lubricant</intervention_name>
    <arm_group_label>Miami w/o frag Personal lubricant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is female between the ages of 18 and 49 years (at lease 21 subjects) or 50-60
             years (no more than 9 subjects);

          -  Subject is using adequate non-barrier method of birth control [established us of
             hormonal methods of contraception (oral, injected, implanted, or patch), intrauterine
             device (IUD) or intrauterine system (IUS), surgical sterilization (e.g. in a
             monogamous relationship with male partner with vasectomy];

          -  Subject is free of any vaginal disorders;

          -  Subject is sexually active and in a monogamous, heterosexual relationship, and whose
             male partner is willing and able to give informed consent and agrees to engage in
             sexual intercourse at least twice each week during the two-week study (at least 50%
             and up to 100% of the study population) or is not sexually active (no more than 50% of
             the population);

          -  Subject is a personal lubricant user and agrees to replace her usual personal
             lubricant with the investigational product;

          -  Subject has normal menstrual cycle and is not expected to menstruate 2-4 days before
             or after the examination days;

          -  Subject agrees to use the provided investigational product at least four times weekly
             (including at least twice weekly during sexual intercourse for subjects with
             monogamous, male partners) over the two-week study period;

          -  Subject exhibits no clinically significant evidence of vulvar or vaginal irritation,
             as determined by a study doctor, and no reports of sensory irritation at the baseline
             examination;

          -  Subject is willing to refrain from introducing any new vaginal products, or using
             vaginal medication or local contraceptives (including condoms and hormonal rings),
             during the course of this study;

          -  Subject agrees to refrain from douching or using any medications, powder, lotions or
             personal care products in the vulvar or perianal area for the duration of the study
             (Note: subjects may continue to use their usual pantyliner, if any);

          -  Subject is willing to use a urine pregnancy test provided to them at baseline and on
             the third visit (Week 2, day 14);

          -  Subject has a standard Clinical Research Laboratories, Inc. (CRL) Medical History form
             on file at CRL and has completed study specific Medical History and Screener/Inclusion
             forms;

          -  Subject has signed and, if sexually active and in a monogamous relationship, whose
             partner has signed, an Informed Consent Form (ICF) in compliance with 21 CFR Part 50:
             &quot;Protection of Human Subjects&quot;;

          -  Subject (and male partner, if applicable) has completed a HIPAA Authorization Form in
             conformance with 45 CFR Parts 160 and 164;

          -  Subject is dependable and able to follow directions as outlined in the protocol;

          -  Subject receives a score of 0 or 0.5 for erythema and edema, and 0 for sensorial
             irritation (burning, stinging, itching, and dryness) during the first examination.

        Exclusion Criteria:

          -  Subject is pregnant, nursing, or planning a pregnancy;

          -  Subject is post-menopausal or has had a hysterectomy;

          -  Subject is currently using, or has used within two weeks prior to study initiation,
             any systemic or topical corticosteroids, vasoconstrictors, antibiotics,
             anti-inflammatories, or antihistamines;

          -  Subject has known allergies to vaginal or any cosmetic products (including lotions,
             moisturizer, powder, sprays, etc.);

          -  Subject reports a history of recurrent bladder, vaginal infection, or incontinence;

          -  Subject exhibits or reports gynecological abnormalities or has had vaginitis within 60
             days prior to study initiation.

          -  Subject is expected to menstruate 2-4 days before or after the time of the first,
             second, and third examination;

          -  Subject uses a vaginal ring, diaphragm or cervical/vault caps, condoms, or condoms
             with spermicide as a means of contraception;

          -  Subject has participated in a study involving the vaginal area or in an
             investigational systemic drug study within two weeks of study initiation;

          -  Subject receives a score higher than 0.5 for erythema, edema, or &gt;0 for burning,
             stinging, or itching, during the first examination or shows any other sign of mucosal
             irregularities (dryness, papules, vesticulation, fissure).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Laboratories</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>October 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2016</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Healthy Subjects</title>
          <description>Novel Personal Lubricant Miami w/o Fragrance</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Healthy Subjects</title>
          <description>Novel Personal Lubricant Miami w/o Fragrance</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age 22-59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Observed Local Erythema</title>
        <description>Number of participants with observed local erythema by OB/GYN examination.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Miami w/o Frag Personal Lubricant</title>
            <description>Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Observed Local Erythema</title>
          <description>Number of participants with observed local erythema by OB/GYN examination.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Observed Local Edema</title>
        <description>Number of participants with observed edema by OB/GYN examination.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Miami w/o Frag Personal Lubricant</title>
            <description>Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Observed Local Edema</title>
          <description>Number of participants with observed edema by OB/GYN examination.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Healthy Subjects</title>
          <description>Novel Personal Lubricant Miami w/o Fragrance</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Master service agreement and confidentiality agreement in place</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Annahita Ghassemi</name_or_title>
      <organization>Church &amp; Dwight Co., Inc.</organization>
      <phone>6098061200</phone>
      <email>annahita.ghassemi@churchdwight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

